Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas - Related Studies

Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas

This study has been completed.

Study NCT00035022. Last updated on January 12, 2006. Information provided by BioCryst Pharmaceuticals

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Leukemia, Lymphocytic
		Lymphoma

2	Additional conditions recognized in this trial
		Leukemia
		Leukemia, Lymphoid

3	More general conditions related to this trial
		Immune System Diseases
		Immunoproliferative Disorders
		Lymphatic Diseases
		Lymphoproliferative Disorders
		Neoplasms
		Neoplasms by Histologic Type

4	Interventions listed in this trial
		BCX-1777

5	Sponsors listed in this trial
		BioCryst Pharmaceuticals